SGLT2 Inhibitor Effects on Inflammation and Heart Disease in Obesity Pilot
Status:
Enrolling by invitation
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
Obesity is associated with increased cardiometabolic disease risk due, in part, to heightened
chronic inflammation arising from adipose tissue. There are no current targeted therapies to
prevent or reverse the chronic inflammation of obesity, and a better understanding of these
inflammatory pathways in humans is key to future therapeutic interventions. This project will
determine both the anti-inflammatory potential of the SGLT2 inhibitor empagliflozin, and the
contribution of adipose inflammation to surrogate measures of cardiovascular disease in a
randomized controlled trial of obese patients.